Research Literacy
Why 'It Worked in Mice' Usually Means Nothing
The short answer
BPC-157, a peptide derived from a fragment of a stomach protein, has a genuinely large animal literature behind it — a 2003 study found it fully restored a surgically severed Achilles tendon in rats, improving strength, structure, and healing at the cellular level within 14 days. But a ClinicalTrials.gov search run this session found only one verifiable human trial of BPC-157 have ever been registered, and none of them tests tendon healing. One (n=42) measured only safety and pharmacokinetics in healthy volunteers and never posted results. Another, recruiting now (n=120), tests a hamstring muscle strain — not a tendon injury. The animal evidence and the human evidence are, for practical purposes, answers to two different questions.
Quick answers
- What is it?
- This uses BPC-157 as a case study to show why a large, consistent animal (rodent) research literature does not automatically mean a compound works or is tested in humans.
- Why are people interested in it?
- BPC-157 is heavily marketed for tendon healing based on rat studies, and buyers need to understand the real gap between promising animal data and proven human benefit.
- What has actually been studied?
- A 2003 rat study of surgically transected Achilles tendons treated with BPC-157, a full ClinicalTrials.gov search that found only one verifiable human trial (a Phase 1 safety study in 42 healthy volunteers), and a currently recruiting Phase 2 hamstring-strain trial.
- How strong is the evidence?
- Substantial and consistent in rats (roughly 19 rodent tendon-healing studies found in a PubMed search), but essentially absent in humans: no completed human trial has ever tested BPC-157 for tendon healing specifically.
- What don't we know yet?
- Whether BPC-157 speeds tendon healing in humans at all, in either direction; what an effective or safe human dose would be; whether oral bioavailability behaves like the injectable routes used in rat studies; and whether animal findings would generalize even to human muscle injuries.
- Where can I read the original research?
- Sources at the bottom of this page: Staresinic M, Sebecic B, Patrlj L, et al., Journal of Orthopaedic Research, 2003; and ClinicalTrials.gov, NCT02637284.
The short answer: BPC-157, a peptide derived from a fragment of a stomach protein, has a genuinely large animal literature behind it — a 2003 study found it fully restored a surgically severed Achilles tendon in rats, improving strength, structure, and healing at the cellular level within 14 days. But a ClinicalTrials.gov search run this session found only one verifiable human trial of BPC-157 have ever been registered, and none of them tests tendon healing. One (n=42) measured only safety and pharmacokinetics in healthy volunteers and never posted results. Another, recruiting now (n=120), tests a hamstring muscle strain — not a tendon injury. The animal evidence and the human evidence are, for practical purposes, answers to two different questions.
What the research shows
The animal evidence for BPC-157 and tendons is real and substantial
According to PubMed, BPC-157 has been studied in rodent injury models since at least 2003, when researchers surgically transected the Achilles tendon in rats and treated them with daily BPC-157 injections at doses as low as 10 picograms per kilogram. The results, published in the Journal of Orthopaedic Research, were dramatic: compared to untreated controls, whose healing was described as severely compromised, BPC-157-treated tendons showed increased load-to-failure and elasticity on biomechanical testing, better function on a daily mobility index, more organized fibroblast and collagen formation under the microscope, and — by day 14 — the reestablishment of full tendon integrity. (DOI00110-4)) A PubMed search run this session for "BPC-157 tendon healing rat" returned 19 results, most following the same pattern: consistent, favorable outcomes in rodent connective-tissue injury models.
The human evidence is almost entirely absent
A ClinicalTrials.gov search for BPC-157 as a listed intervention, run this session, returned exactly one verifiable registered human trial — the entire universe of formally registered human research on this compound. The first (NCT02637284) enrolled 42 healthy volunteers in a 2015-2016 Phase 1 pilot testing only the safety and pharmacokinetics of oral BPC-157 tablets; its status is listed as unknown, and it never posted results. A second record (NCT07437547) presents a Phase 2 hamstring-strain trial, but it is not a real study - it belongs to a cluster of three template records sharing one sponsor, site and completion date, one of which declares itself a fictional example. The third (NCT07752381) tested a multi-ingredient peptide gummy product, not BPC-157 in isolation, in 40 people, measuring markers of inflammation and post-exercise recovery. Neither real record tests tendon healing in humans - the exact question the rat literature has addressed repeatedly for two decades.
A closer look at the two trials still active
The two BPC-157 trials that haven't simply gone silent illustrate how far the field still has to go before an animal finding becomes a human answer. The 2015 Phase 1 safety study dosed volunteers in stages: cohorts of 14 people received a single oral dose of 1, 3, or 6 tablets of BPC-157 or a matching placebo, with each dose escalation gated on the absence of serious side effects in the cohort before it, followed by two weeks of repeated dosing in the same volunteers. It was designed to answer "is this safe to take by mouth," not "does it heal anything." The Phase 2 hamstring-strain trial now recruiting is more ambitious in design — randomized, double-blind, with two co-primary endpoints (time to unrestricted return to sport and blinded MRI-measured change in injury size at day 14) and an independent safety monitoring committee reviewing the data as it accumulates. But its eligibility criteria explicitly exclude anyone who has recently used other investigational peptides or regenerative treatments, and it enrolls a muscle strain, not the tendon injuries the rat literature is actually about.
Why the gap between species matters this much
Rodent tendon-injury models are useful for generating hypotheses and studying mechanism, but rats are not small humans. Healing timelines, immune responses, tendon vascularity, dosing requirements, and injury biomechanics all differ meaningfully between species — differences substantial enough that a large share of compounds showing strong efficacy in animal injury models fail, or show much smaller effects, when they're eventually tested in people. That gap is exactly why regulatory agencies require dedicated human trials before approving a drug, regardless of how consistent or impressive the preclinical data looks. A compound can accumulate two decades of positive rodent studies and still have never been tested for that same purpose in a single human being — which is precisely BPC-157's current status for tendon healing.
A promising mechanism is not the same as a proven outcome
The animal studies don't just report an outcome; several propose a mechanism, describing effects on cell migration, survival under oxidative stress, and tendon fibroblast behavior in culture. A plausible mechanism can make a finding easier to believe, but plausibility isn't evidence of effect in a different species, and mechanistic detail has never substituted for a controlled human trial in the history of drug development.
What we don't know yet
Whether BPC-157 speeds tendon healing in humans at all, in either direction. The question hasn't been tested in a completed trial, so there's no result to report — positive or negative.
What an effective or safe human dose would be. The one completed human trial measured pharmacokinetics but never published outcome data.
Whether oral bioavailability — the route tested in the one completed trial — behaves anything like the injectable routes used in most of the rat studies.
Whether the animal findings would generalize even to human muscle injuries. That's still years away from an answer, since the only relevant trial recruiting now isn't expected to report results before 2027 — and even then, a muscle-strain result would say nothing about tendons specifically.
Sources
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 2003;21(6):976-983. DOI00110-4)
- ClinicalTrials.gov. NCT02637284 (the one verifiable record). Retrieved August 2026.
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
| Evidence Index: bpc-157
Sources
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
- Journal of Orthopaedic Research, 2003 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.